Podcasts about Melanoma

What began as a harmless looking spot on Kevin Donaghy's forearm turned into a pair of diagnoses of skin cancer.  The first was Stage II in 2018, but 18 months later, it returned and was diagnosed Stage IV metastatic melanoma BRAF+.  The urologist said Kevin, an IT specialist from Melrose, Scotland, may have six months to live unless he underwent a newly-approved immunotherapy known as pembroluzimab.  That was in 2020, and Kevin is still with us.  The immunotherapy triggered a bout of ulcerative colitis, which left him bedridden for six months, but Kevin says his health is no different than it was before his diagnosis.   In late 2017, Kevin didn't give much thought to a spot he saw on his forearm.  He thought he might have cut himself and didn't know it.  When the spot didn't go away, he sought medical attention.  His doctor said the spot did not look cancerous, prescribed some cream for Kevin to rub on it, and said if the spot changes in size, shape or color, to come back.  The spot made none of those changes, but it also didn't go away.   Kevin was referred to a dermatologist, who called for a biopsy.  He was away on a business trip when he received an urgent phone call stating that Kevin needed to come in that afternoon.  He came in two days later and the dermatologist said the biopsy indicated Kevin had a cancerous tumor in his forearm.  Another biopsy was conducted to see if the cancer had spread to any lymph nodes and thankfully it hadn't.   Not long after the tumor was removed, Kevin received a phone call from the oncologist while walking in downtown Edinburgh.  The doctor told Kevin he was cancer free.  On the sidewalk, he dropped to his knee and wept, overcome with relief.  He thought the worst was over.   However, his health took a turn for the worse some 18 months later when he experienced severe back pain and sought medical attention.  Another biopsy revealed that the melanoma had spread, bypassing his lymph nodes, but resulting in tumors on his right lung and one next to his spine, which was the source of back pain.   Kevin was told he had six months to live unless a procedure involving an immunotherapy called pembroluzimab was successful.  The operation seemed to go well, but at its conclusion, Kevin had to periodically come in for CT scans.  A couple years later, Kevin was contacted by his urologist who said the immunotherapy had shrunk the tumors and again, he was told he was cancer free.   There was one more problem for Kevin.  The immunotherapy triggered ulcerative colitis, a chronic inflammatory disease.  He was bedridden for six months, but eventually survived that as well.   These days Kevin Donaghy says his health is just as sharp as it was prior to his diagnosis, and that going forward he "wants to do more."   He has gone on to write a book, "Stories of Hope and Cancer."  Thousands of copies have been donated to cancer charities around the United Kingdom.  It chronicles the stories of 39 cancer survivors.   Additional Resources:   Kevin's book: "Stories of Hope and Cancer," available on Amazon, with proceeds going to cancer charities throughout the United Kingdom.  

When standard-of-care checkpoint blockade fails in metastatic melanoma, how can oncologists and interventional radiologists join forces to turn around patient outcomes? In this episode of the BackTable Podcast, medical oncologist Dr. Jennifer McQuade and interventional radiologist Dr. Rahul Sheth join host Dr. Tyler Sandow to discuss the growing evidence for intratumoral oncolytics as a therapeutic strategy for frontline immunotherapy-refractory melanoma and the interdisciplinary work that is required for successful implementation in practice. --- SYNPOSIS The physicians review how engineered viral vectors, particularly RP1, complement checkpoint blockade through direct tumor lysis and immune activation, and summarize the IGNYTE trial data supporting their use in patients with metastatic melanoma refractory to anti-PD-1 and anti-CTLA-4 agents. The discussion then shifts to practical administration, highlighting the central role of interventional radiology in delivering these therapies to visceral and deep-seated lesions under image guidance. The doctors go on to address the nuances of patient and lesion selection, injection technique, and response assessment, including the importance of recognizing pseudo-progression. They place particular emphasis on the need for multidisciplinary collaboration and stakeholder buy-in efforts on the part of IRs seeking to integrate intratumoral oncolytic injections into their scope of practice. The episode concludes with a forward-looking discussion on the potential for expansion of oncolytic platforms into other solid tumors, underscoring this field as a growing, IR-forward frontier in cancer treatment. --- TIMESTAMPS 00:00 - Introduction02:28 - Immunotherapy Basics06:51 - How Oncolytic Viruses Work11:01 - IGNYTE Trials and Why IR Matters18:14 - T-VEC vs RP1 Indications and Logistics21:57 - Physician Communication and Multidisciplinary Treatment23:06 - RP1 Protocol and Administration Techniques30:28 - RP1 Safety Profile32:46 - Follow-Up Imaging and Response Assessment35:44 - Future Applications Beyond Melanoma41:42 - Final Thoughts and Closing Remarks --- RESOURCESWong MK, et al. RP1 Combined With Nivolumab in Advance Anti-PD-1-Failed Melanoma (IGNYTE). J Clin Oncol. 2025;43(33):3589-3599.https://doi.org/10.1200/jco-25-01346 IGNYTE-3 Trialhttps://clinicaltrials.gov/study/NCT06264180

Ocular melanoma is one of the rarest forms of cancer — and because of that, it's often misunderstood.   In Episode 4 of My 15 Years, Melody talks about some of the most common misconceptions surrounding ocular melanoma, including funding challenges that come with such a rare diagnosis.   She also reflects on what advocacy looked like in the early days of her journey, when awareness of ocular melanoma was limited and resources for patients were far fewer than they are today. Melody shares how those early experiences helped shape her commitment to raising awareness and supporting the ocular melanoma community.   This episode sheds light on the realities of living with a rare cancer and the importance of advocacy, education, and community.

The sound of regional Australia. News and analysis from the ABC's network of regional reporters.

Tumor-infiltrating lymphocyte (TIL) cell therapy is a promising option for patients with advanced melanoma, but logistical and referral challenges can be a barrier to care. In this episode, CANCER BUZZ speaks with Lilit Karapetyan, MD, MS, FACP, medical oncologist at Moffit Cancer Center and Research Institute, an authorized treatment center (ATC) for TIL cell therapy, and Raju Vaddepally, MD, hematologist-oncologist at Florida Cancer Specialists, a non-ATC, about the referral process. Both guests discuss the relationship between their cancer programs, offering actionable tips on how to streamline the identification and referral of melanoma patients for TIL therapy across institutions. Guests:  Lilit Karapetyan, MD, MS, FACP Medical Oncologist Moffitt Cancer Center and Research Institute Tampa, FL Raju Vaddepally, MD   Hematologist-Oncologist Florida Cancer Specialists Naples, FL  "It is extremely important that providers think about this earlier, because the huge issue that we have with TIL therapy is that we get a lot of patients referred but unfortunately, they are no longer fit to proceed with the therapy." - Lilit Karapetyan, MD, MS, FACP "Cancer care can be so fragmented and always requires multidisciplinary input, whether it be within the town or going to an academic center, so we do have a specialized department in which they handle all these referrals." - Raju Vaddepally, MD Resources ACCC TIL Therapy Resources ACCCBuzz Blog: Streamlining TIL Cell Therapy: ACCC Resources to Improve Referral Pathways and Academic–Community Coordination CANCER BUZZ: Developments in TIL Cell Therapy  

Shelley didn’t see herself as “an honoree.” She saw herself as a working mom in a male‑dominated industry who just wanted to stay ahead of breast cancer. In this conversation, she walks us through the mammogram she almost didn’t get, receiving the news of a Stage 0 DCIS diagnosis, and the 10 years of follow‑up, skin checks, and colonoscopies that followed. Her story reminds us that early detection, asking questions, and having access to care—like the care The Rose offers uninsured and underinsured women—can change everything. She also shares why she’s using her role at this year's Everything’s Coming Up Roses Luncheon to spotlight access to mammograms and diagnostics for women who can’t afford them. Please consider sharing this episode, or making a donation at therose.org so more women receive breast cancer screening and care. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. Key Questions Answered What led Shelley to push for her first 3D mammogram at 41 instead of waiting until 50? How did her history—friends with breast cancer in their 30s and a family member who died—shape her sense of urgency? What does a stage zero DCIS diagnosis mean, and why did she wrestle with whether it “counted” as breast cancer? How did Shelley decide on a shorter, more intense “Canadian” radiation regimen, and what side effects did she experience? How did she talk to her husband and young son about her diagnosis without overwhelming them? In what ways did her workplace support her through biopsy, lumpectomy, and radiation so she could keep working? How did ringing the bell—and seeing her mother there—change how she processed the whole experience emotionally? Why did she become more assertive with doctors about mammograms, Pap smears, and other screenings after cancer? How did later health scares—melanoma on her back and her husband’s colon cancer—reinforce her commitment to early detection? What does Shelley hope listeners understand about The Rose’s role in providing mammograms, diagnostics, and treatment navigation for uninsured and underinsured women? Timestamped overview 03:30 Honoree at Everything’s Coming Up Roses, Shelley’s background as a mom and plastics industry leader, and her mother’s role as a business owner. 07:30 Pushing for an early mammogram at almost 40, getting delayed, then insisting at 41 on a 3D mammogram because of friends and family lost to breast cancer. 10:00 Calcifications, biopsy, lumpectomy, and hearing “stage zero DCIS”; becoming a “Google doctor” and wrestling with whether stage zero “counts” as cancer. 14:30 Choosing a four‑week Canadian radiation regimen, handling side effects, staying organized with questions for every doctor, and finishing treatment. 18:30 Ringing the bell, being surprised by her mom, finally breaking down, and how her kids processed “Mommy is sick but getting treated.” 22:30 Work support, flexible leave, staying on the job through treatment, and the relief of not having to fight employers while fighting cancer. 26:00 Living as a pragmatic, matter‑of‑fact patient, annual anxiety around scans, pushing for Pap smears and colonoscopies, and learning to question doctors. 29:00 Melanoma diagnosis, yearly (now more frequent) skin checks, taking her kids for annual skin exams, and teaching them why preventative care matters. 30:16 Her husband’s colon cancer, why “cancer” is both a scary and hopeful word in their home, and what it means to step into the honoree role to support The Rose’s mission of early detection and access to care for women who can’t afford it.See omnystudio.com/listener for privacy information.

Whalehead Deadbear Brainworm-Lamprey went to Austin (where his pal who wants people to get Polio lives) and told the peasants to eat more cheap, nasty cuts of meat. He wasn't talking that way back when he ate veal from my plate aboard a cruise ship in the Caribbean. Bill Clinton puts the lie to Nitwit Nero's claim about when he stopped having anything to do with Epstein. And since they subpoenaed Hillary, they opened the door to deposing Melanoma. And she IS in the TrumpStein files!

Decades ago, tattoos were often considered the domain of sailors who loved images of…

Experts say a proposal for Pharmac to widen access to two medicines for advanced melanoma will improve outcomes. Oncologist Dr Gareth Rivalland spoke to Corin Dann.

On the Early Edition with Ryan Bridge Full Show Podcast Wednesday the 25th of Feburary 2025, nurses at aged care facilities are going back to paper-based prescriptions after Medimaps data breach, Former Health NZ Chair shares his concerns. Christchurch bar owners say Anzac Day liquor laws will ‘shut the city down' on the new stadium's opening night, Jeremy Stevens Hospitality NZ Canterbury Branch President tells Ryan how much it'll impact bars. Pharmac's looking at funding two new Melanoma drugs, medical oncologist and Melanoma specialist Dr Gareth Rivalland tells Ryan how big of a difference the drugs would make. UK/ Europe Correspondent Gavin Grey has the latest on trade minister Chris Bryant calling Andrew Mountbatten-Windsor as a "rude, arrogant and entitled man" and a baby boy has become the first child in the UK to be born using a womb transplanted from a dead donor. Get the Early Edition Full Show Podcast every weekday on iHeartRadio, or wherever you get your podcasts. LISTEN ABOVE See omnystudio.com/listener for privacy information.

New treatment options for melanoma are being described as the global gold standard. Pharmac's proposing to increase access to nivolumab and ipilimumab for treating stage 3b and 4 melanoma, from May. Pre-surgery use of the immunotherapy drugs can lower the chance of cancer returning. Medical oncologist Dr Gareth Rivalland told Ryan Bridge it's state of the art treatment. He says it's the best combination and will kill off the cancer in 60% of people. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Dr. Raymond Barnhill on Diagnostic Drift, Uncertainty, and the MPATH-Dx V2.0 Approach to Melanocytic LesionsIn this episode of The Girl Doc Survival Guide, Christine interviews Dr. Raymond Barnhill, a world-recognized dermatopathology expert known for work on diagnostically challenging melanocytic lesions, melanoma pathology references, and contributions to WHO skin tumor classification and AJCC melanoma staging. Dr. Barnhill shares career anecdotes and key communities at Yale and in Boston, collaborations with numerous melanoma leaders, and the founding of the North American Melanoma Pathology Study Group and the International Melanoma Pathology Study Group, as well as participation in the NIH-funded MPATH Study Group. The discussion focuses on overdiagnosis, underdiagnosis, and diagnostic discordance in melanocytic lesions, including evidence of diagnostic drift toward calling more lesions melanoma over time and the overlap between melanoma criteria and atypical/dysplastic nevi. He describes MPATH research, explains the revised MPATH-Dx V2.0 schema, explicitly recognizing uncertainty along a continuum rather than a strict benign/malignant threshold. He emphasizes practical diagnostic approaches including measuring lesion size (noting a 4 mm threshold associated with conventional dysplastic nevi and increasing concern at larger sizes), focusing on key architectural features (junctional nest variation/disarray and lentiginous proliferation), using nuclear size relative to keratinocyte nuclei (including a 1.5× threshold and counting atypical cells per high-power field) while accounting for site-specific pitfalls such as scalp nevi. The conversation also covers “gestalt” versus systematic review, the importance of due diligence using full clinical and morphologic information before ancillary testing, and cautions against overreliance on immunohistochemistry or molecular tests. Dr. Barnhill closes with career advice ends with a message that setbacks can be opportunities for growth.00:00 Welcome + Meet Dr. Raymond Barnhill (Dermatopathology Legend)01:51 Career Origins & Melanoma Pathology Mentors (Yale → Boston)03:59 Building Melanoma Pathology Study Groups (North American & International)05:57 Overdiagnosis, Diagnostic Drift & Why Discordance Happens09:43 Inside the MPATH Study: Measuring Interobserver & Intraobserver Agreement11:39 MPATH-Dx V2.0 Explained: Standardized Classes & Treatment Guidance13:59 Redefining “Low-Risk” Melanoma: Stringent pT1a Criteria + Embracing Uncertainty18:47 Practical Grading Tips: Lesion Size, Architecture & Nuclear Atypia Thresholds22:42 Gestalt vs Due Diligence: Avoiding Traps + Using IHC/Molecular Wisely (PRAME)28:39 Career Advice: Passion, Mentors, Community + Final Reflections

Join the Behind the Knife Surgical Oncology Team as we discuss the PRADO and NADINA randomized control trials regarding neoadjuvant therapy in Stage III melanoma with macroscopic nodal disease!Hosts:Timothy Vreeland, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center.Daniel Nelson, DO, FACS (@usarmydoc24) is Surgical Oncologist/HPB surgeon at Kaiser LAMC in Los Angeles.Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a 2ndYear Surgical Oncology fellow at MD Anderson.Beth (Elizabeth) Barbera, MD (@elizcarpenter16) is a General Surgery physician in the United States Air Force station at RAF Lakenheath.Joe (Joseph) Broderick, MD, MA (@joebrod5) is a General Surgery research resident between his second and third year at Brooke Army Medical Center.Galen Gist, MD (@gistgalen) is a General Surgery research resident between his second and third year at Brooke Army Medical Center. Learning Objectives:-       Evaluate the role of Completion Lymph Node Dissection (CLND) in patients with positive sentinel lymph nodes, specifically citing the lack of melanoma-specific survival benefit vs. the improvement in regional disease control demonstrated in the MSLT-II trial.-       Determine the appropriate surgical excision margins for primary cutaneous melanoma, comparing the outcomes of 1 cm versus 2 cm margins as analyzed in the MINT trial (Lancet 2019).-       Analyze the impact of adjuvant systemic therapy (Anti-PD1/Immunotherapy) on recurrence-free survival in patients with resected high-risk Stage III melanoma.References:Reijers, I.L.M., Menzies, A.M., van Akkooi, A.C.J. et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med 28, 1178–1188 (2022). https://doi.org/10.1038/s41591-022-01851-xChristian U. Blank et al. Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.. J Clin Oncol 42, LBA2-LBA2(2024). DOI:10.1200/JCO.2024.42.17_suppl.LBA2*Sponsor Disclaimer: Visit goremedical.com/btkpod to learn more about GORE® SYNECOR Biomaterial, including supporting references and disclaimers for the presented content.  Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

El Dr. Carlos Alberto Ronquillo Carreón, oncólogo médico del Centro Médico Nacional de Occidente del IMSS, participa en el Taller de Residentes de Oncología Médica RISE, 8.ª edición, donde aborda el melanoma.Fecha de grabación: 17 de enero de 2026.Material exclusivo para profesionales de la salud. Este material ha sido desarrollado únicamente con fines educativos e informativos, para uso personal, y no tiene la intención de sustituir el juicio clínico de los profesionales de la salud.El contenido, las opiniones y declaraciones presentadas son responsabilidad exclusiva de los ponentes y no reflejan necesariamente la postura institucional de ScienceLink ni de terceros mencionados. La información presentada se basa en el conocimiento y la experiencia profesional de los ponentes. La veracidad, exactitud y actualidad científica de los datos son de su exclusiva responsabilidad. Así mismo garantizan que el contenido utilizado no infringe derechos de autor de terceros y asumen toda responsabilidad por su uso.ScienceLink y los terceros mencionados no se responsabilizan por daños o consecuencias derivados del uso, interpretación o aplicación de la información, ni por errores u omisiones.Se deberán de revisar las indicaciones aprobadas en el país con estricto apego al marco regulatorio aplicable para cada uno de los tratamientos y medicamentos comentados.

Episode 3: Ocular Melanoma 101 & My Treatment Experience   Understanding a rare cancer can feel overwhelming — especially at the moment of diagnosis.   n Episode 3 of My 15 Years, Melody breaks down the basics of ocular melanoma (OM 101) in a clear, approachable way. She explains what ocular melanoma is, and how she felt as a newly diagnosed patients.   Melody also goes deeper into her personal treatment experience, sharing what plaque brachytherapy was like — from preparing for the procedure to living through treatment and recovery.   This episode is designed to help patients, caregivers, and loved ones better understand ocular melanoma, while grounding the information in real lived experience.   Rare Cancer. Resilient Hope. Revolutionary Research.

We discuss three pivotal studies showing how natural light wavelengths positively influence health from all-cause mortality to visual perfomance to blood glucose control in Type II diabetics.Jonathan Jarecki is a biomedical science sophomore with an interest in light and health, and host of Whole Health Podcast. SUPPORT MY WORK

O Check-up Semanal é um formato do Portal Afya que reúne, em um único episódio, um resumo comentado dos cinco temas mais relevantes de cada especialidade, com base nos conteúdos publicados recentemente no portal.No episódio de hoje do Check-up Semanal, o Dr. Ronaldo Gismondi, editor-chefe médico do Portal Afya e do Whitebook, comenta os principais destaques recentes em Dermatologia publicados no Portal Afya.

What would you discover about yourself if you lost everything you thought defined you…What happens when a 4x4 truck ends your professional running career at 20? Rob Rene found out. Then the pandemic took his corporate identity. Then came stage 3 melanoma. Three devastating transitions. Three chances to give up. Instead, Rob discovered faith isn't about Sunday church—it's daily relationship with God. He researched our broken medical system, learned his cancer's specific mutation, and fought back naturally. Fourteen months later, his tumors have shrunk 50%. "Fighting cancer is about starving it and getting your immune system strong enough to attack." Rob now helps others through Exodus Strong and Biohackingville, merging biblical wisdom with modern science. His message: if you have breath in your lungs, God still has a plan.Rob Rene is a faith-based AI wellness futurist, founder of Exodus Strong and creator of Biohackingville. After a truck accident ended his professional running career at age 20, he spent 20+ years in corporate sales before the pandemic sparked his deep dive into holistic health research. Currently battling stage 3 melanoma naturally (tumors down 50% in 14 months), Rob merges biblical wisdom with modern science through his products and community. His work focuses on four pillars: red light therapy, frequency medicine, molecular hydrogen supplementation, and faith. He hosts the "I Am Pain Free Podcast" and lives with his blended family.About The Show: The Life in Transition, hosted by Art Blanchford focuses on making the most of the changes we're given every week. Art has been through hundreds of transitions in his life. Many have been difficult, but all have led to a depth and richness he could never have imagined. On the podcast Art explores how to create more love and joy in life, no matter what transitions we go through. Art is married to his lifelong partner, a proud father of three and a long-time adventurer and global business executive. He is the founder and leader of the Midlife Transition Mastery Community. Learn more about the MLTM Community here: www.lifeintransition.online.In This Episode: (00:00) The First Truck: Career-Ending Accident(06:05) Looking in the Mirror: Identity Crisis(14:39) Accepting God's Plan After Loss(19:24) Twenty Years of Corporate Success(22:10) The Second Truck: Pandemic Awakening(27:28) Uncovering Medical System Corruption(33:38) Reading the Bible and Finding Faith(43:28) Red Light Therapy and Holistic Healing(54:18) The Third Truck: Stage 3 Melanoma(1:04:41) Tools for Navigating Major Transitions(1:09:28) Exodus Strong and Biohackingville ResourcesLike, subscribe, and send us your comments and feedback.Resources:Company Website: ExodusStrong.com - Biblical wellness supplements with red light therapyCommunity Platform: Biohackingville.com - Natural health repository and communityI am Pain Free Podcast: https://www.youtube.com/@IAmPainFreeEmail Art BlanchfordLife in Transition WebsiteLife in Transition on IGLife in Transition on FBJoin Our Community: https://www.lifeintransition.online/My new book PURPOSEFUL LIVING is out now. Order it now: https://www.amazon.com/PURPOSEFUL-LIVING-Wisdom-Coming-Complex/dp/1963913922Explore our website https://lifeintransitionpodcast.com/ for more in-depth information and resources, and to download the 8-step guide to mastering mid-life transitions.The views and opinions expressed on the Life In Transition podcast are solely those of the author and guests and should not be attributed to any other individual or entity. This podcast is an independent production of Life In Transition Podcast, and the podcast production is an original work of the author. All rights of ownership and reproduction are retained—copyright 2025.

Roger Seheult, MD of MedCram examines a new UK BioBank study on sunlight comparing melanoma mortality risk with all cause mortality benefit. See all Dr. Seheult's videos at: https://www.medcram.com/ (This video was recorded on January 24th 2026) Roger Seheult, MD is the co-founder and lead professor at: www.medcram.com He is Board Certified in Internal Medicine, Pulmonary Disease, Critical Care, and Sleep Medicine and an Associate Professor at the University of California, Riverside School of Medicine. MEDCRAM WORKS WITH MEDICAL PROGRAMS AND HOSPITALS: MedCram offers group discounts for students and medical programs, hospitals, and other institutions. Contact us at customers@medcram.com if you are interested. MEDIA CONTACT:  Media Contact: customers@medcram.com Media contact info: https://www.medcram.com/pages/media-contact Video Produced by Kyle Allred Edited by Daphne Sprinkle of Sprinkle Media Consulting, LLC FOLLOW US ON SOCIAL MEDIA: Facebook:  www.facebook.com/MedCram Twitter/X: www.twitter.com/MedCramVideos Instagram: www.instagram.com/medcram DISCLAIMER: MedCram medical videos are for medical education and exam preparation, and NOT intended to replace recommendations from your doctor. #sunlight #melanoma #infrared

In Conversation with Dr. Wolfgang Weyers: The Complexities of Dermatopathology DiagnosisIn this episode of The Girl Doc Survival Guide, Christine welcomes Dr. Wolfgang Weyers, a highly respected dermatopathologist and author, to discuss his experience and perspectives on medical diagnosis. Dr. Weyers shares a personal anecdote about his influential mentor, Dr. Bernie Ackerman, and dives into a critical discussion on overdiagnosis, the importance of specific diagnosis in dermatopathology, problems caused by partial samples, and the criteria for diagnosing melanoma. He emphasizes the importance of experience, proper training, and the need to biopsy adequately developed lesions. The conversation also touches on the complexity of biological classification and the role of behavior and molecular studies in understanding diseases. 00:00 Introduction to Dr. Wolfgang Weyers00:46 Personal Anecdotes and Influences02:05 Discussion on Overdiagnosis05:04 Criteria for Melanoma Diagnosis08:34 Challenges in Diagnosis and Solutions16:48 Final Thoughts and Conclusion

In this episode of the Eye Believe Podcast, we're joined by Dr. Hadfield, a medical oncologist treating uveal melanoma patients in the Northeast, for an in-depth discussion of the most important takeaways from ESMO 2025. Dr. Hadfield breaks down key study results and emerging data from major trials, including the CHOPIN Trial, Immatics Trial, IDEAYA Trial, and more—offering expert insight into what these findings may mean for patients, caregivers, and the future of uveal melanoma treatment. Links mentioned in this episode Q1 Eye on the Experts Webinar: Eyes on the Chopin Study: What does this mean for patients? https://events.zoom.us/ev/AgpsCnGSA4Hnib_afWXvh5jNq0qqSTvpKhOB8xHg0M9cItAlsoSw~Ah8MbImmpM---YQJIycJ2xa5cdZV0t5y8JSYZGuk2DnZJoO6vsGncOFduA ACIS Physician Finder: https://acureinsight.org/resources/ - click physician finder ACIS Metastatic Treatment Resources (including the July 2025 updated clinical trial summaries of enrolling trials): https://acureinsight.org/metastatic-om/ ASCO Fiber Study 2025: https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.9511 Summary of Studies discussed from attendance at ESMO: (https://acureinsight.org/acis-summary-of-uveal-melanoma-um-presentations-abstracts-and-posters-at-the-annual-meeting-of-the-european-society-for-medical-oncology-esmo-october-17-21-2025-berlin-germany/ ACIS NEWS RELEASES: follow along and subscribe to our newsletter to see the latest updates as we have them. https://acureinsight.org/ocular-melanoma-news/ Whether you're a patient, advocate, or clinician, this episode provides a clear and accessible overview of the latest research shaping the uveal melanoma landscape. Tune in to learn what's new, what's promising, and where the field may be headed next.

The treatment landscape for melanoma continues to evolve at a rapid pace, with new clinical trial data and therapeutic modalities refining how clinicians approach both early-stage and advanced disease. Michael A. Davies, MD, PhD, Professor and Chairman of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, recently chaired i3 Health's CME/NCPD/AAPA activity, "Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes." With numerous new developments in melanoma treatment over recent months, Dr. Davies sat down again to share these critical updates that are impacting practice. After the interview, stay tuned to hear module 2 of the full podcast activity. Click the link to complete module 2 and claim your free credit: bit.ly/44yO9RB

The treatment landscape for melanoma continues to evolve at a rapid pace, with new clinical trial data and therapeutic modalities refining how clinicians approach both early-stage and advanced disease. Michael A. Davies, MD, PhD, Professor and Chairman of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, recently chaired i3 Health's CME/NCPD/AAPA activity, "Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes." With numerous new developments in melanoma treatment over recent months, Dr. Davies sat down again to share these critical updates that are impacting practice. After the interview, stay tuned to hear module 1 of the full podcast activity. Click the link to complete module 1 and claim your free credit: bit.ly/4iYmYD2

In this eye-opening episode with Nadine Artemis, author of Renegade Beauty and Holistic Dental Care, we challenge everything you thought you knew about the sun. She unpacks why sunlight has become so controversial, tracing the history of heliotherapy and the very real biological need humans have for natural light. Nadine dives into the surprising benefits of sun exposure even in the winter, how light entering the eyes affects our hormones, and what the melanoma research actually shows when you look beyond the headlines. The conversation takes a bold turn as she exposes the real issues with modern sunscreen, explores vitamin D–rich foods in cold climates, and explains the deep connection between sunlight, bone health, and strong teeth. We also discuss tanning beds, the melanotan peptide, melatonin as a form of internal sun protection, and what our skin was truly designed to do. Packed with practical daily sun and light guidance, this episode will completely reshape how you think about sunshine, skin health, and long-term vitality. Nadine Artemis, the author of Renegade Beauty and Holistic Dental Care, is the creator of Living Libations, a pure and luxurious line of organic oral care, botanical beauty care, and medicinal elixirs often called the “holy grail” of wholesome skincare. Artemis is an innovative aromacologist, and her healing formulations and her concept of renegade beauty encourage effortlessness, engaging with the elements, and inspires people to rethink conventional notions of wellness and beauty. She is a key speaker at health and wellness conferences and has received glowing reviews in the Hollywood Reporter, GOOP, Vogue, People, Elle, Yoga Journal, Natural Health, W Magazine, The New York Times, Forbes, Los Angeles Times, and National Post.SHOW NOTES:0:40 Welcome to the podcast!2:49 About Nadine Artemis3:23 Welcome her to the show!5:36 Why is the sun so polarizing?8:06 History and research on heliotherapy11:29 Biological need for sun's rays13:17 Benefits of the sun in the winter16:52 Sunglasses & light in your eyes17:11 Melanoma study18:59 The real problem with sunscreen21:45 Vitamin D foods in cold climates24:30 Bone health & teeth25:57 *ELLIE MD*27:46 Tanning & Melanotan32:39 Melatonin as sun protection38:41 Protecting your face44:12 What our skin is designed for46:42 Daily sun & light advice53:45 Her final piece of advice54:40 Living Libations55:54 Thanks for tuning in!RESOURCES:ELLIE MD PeptidesFollow Nadine:Website: https://livinglibations.comIG: @nadineartemisofficial / @livinglibationsofficial Facebook: @LivingLibations @nadineartemisofficial Twitter/X / @LivingLibationsBook: Myth on MythSperti Vitamin D Lamp - 10% off with code: BIOHACKERBABESDMinder AppSunHugg - 10% off with code: BIOHACKERBABESBiolongevity Labs (Melanotan Peptide) - Discount code: BIOHACKERBABESSupport this podcast at — https://redcircle.com/biohacker-babes-podcast/donationsAdvertising Inquiries: https://redcircle.com/brands

Concerns over skin cancer with many Kiwis still getting sunburnt. A new Cancer Society and Otago University survey, has found 64% of respondents were sunburnt at least once last summer, including 26% severely. Rates were highest among 18 to 24-year-olds, with more than a third reporting at least three sunburns. Dr Bryan Betty joined Jack Tame to break down the data and discuss some of the best ways to push skin protection to the youth. LISTEN ABOVE See omnystudio.com/listener for privacy information.

To have Dr. Morse answer a question, visit: https://drmorses.tv/ask/ All of Dr. Morse's and his son's websites under one roof: https://handcrafted.health/ Facebook Page: https://www.facebook.com/handcrafted.health 00:00:00 - Intro - Health - The Medical World - and much more! 00:29:18 - Accutane - Update - Eye Pictures 00:52:05 - Blood Sugar 00:59:39 - Stage 3 Melanoma Cancer - Thyroid Cancer 01:43:30 - Anxiety and Panic attacks - Lethargic - Lack of Periods - Low Blood Pressure - Constipation 01:59:35 - Seed oils 02:03:38 - Conception  00:29:18 - Accutane - Update - Eye Pictures After a week of doing the diet and herbs, my life did a complete 180, it was the craziest experience ever! 00:52:05 - Blood Sugar I have a question about being on an all-fruit /vegetable diet. 00:59:39 - Stage 3 Melanoma Cancer - Thyroid Cancer They cut out her entire thyroid and I think the parathyroids too.  01:43:30 - Anxiety and Panic attacks - Lethargic - Lack of Periods - Low Blood Pressure - Constipation Do antidepressants cause you to get worse?  01:59:35 - Seed oils Do you agree that seed oils are some of the worst things you can eat? 02:03:38 - Conception  In the past 4 years I've tried many different things in order to conceive, nothing seems to be working.

Melanoma survivor Leah Koskinen joins me to break down what every family needs to know about sun safety. We talk about the real risks behind sunburns and tanning, how to spot concerning moles early, and why year-round protection matters more than most people realize. Leah also shares practical, mom-friendly strategies for choosing sunscreen, using UPF clothing, and getting enough vitamin D without damaging your skin. Click HERE to access the show notes for this episode. 

New Zealand has the world's highest melanoma death rate, but University of Auckland scientists hope a $1 million grant will help bring a new treatment to patient trials in just over five years. Associate Professor of Pharmacology Stephen Jamieson spoke to Lauren Crimp.

While jogging in 2023, Tessa Parry-Wingfield felt an unusual sensation in her left eye.  It wasn't painful but merited medical attention.  She was seen by three doctors before learning she had ocular melanoma, a form of eye cancer.  Because of the particulars of her diagnosis, she had to undergo an enucleation, the removal of her cancerous eye.  With an acrylic implant taking the place of the cancerous eye, Tessa had an enormous amount of learning ahead of her, most notably what is known as monocular vision.  Amazingly, Tessa has adjusted to her limited vision.  She has resumed running and hiking and driving a car.  Her future includes writing a book and climbing Mt. Kilimanjaro.   Tessa was jogging along the River Thames in London when she felt something was wrong with her left eye.  She went to see an optician thinking she needed to change her prescription regarding her contact lenses.  However, upon checking out Tessa's eyes, the optician could see something was wrong, perhaps an astigmatism.   Lacking the necessary equipment for more in-depth scrutiny, the optician sent Tessa to an eye hospital, where they performed various x-rays and scans.  When one of the x-rays of her left eye was held up for observation, half of it was black.  Her care team thought Tessa had a form of eye cancer known as ocular melanoma, or, uveal melanoma, a tumor in the eye.  She was next sent to see an ocular oncologist, who swiftly confirmed the diagnosis.   Many patients diagnosed with ocular melanoma have more than one treatment option, but in Tessa Parry-Wingfield's case, the oncologist performed more scans and tests and immediately told her she would need to undergo an enucleation, the removal of her left eye.    Tessa was under anesthesia for the 90-minute procedure.  It resulted in her getting a temporary prosthetic eye, eventually replaced by an acrylic implant, which she has to this day.   She had to do a great deal of learning to go through daily life with one functioning eye, but that is exactly what Tessa has done.  She has resumed running, hiking and skiing.  She thought it would be a year or so of adjustments before she could drive a car, but her vision tests went so well that, three months after the procedure, her oncologist urged her to get behind the wheel.  Without a left eye, she says she has to look a little farther to the left than she was used to before her diagnosis, but she is now quite comfortable driving a car.   Through her cancer experience, Tessa Parry-Wingfield says she has surprised herself by learning how tough and resilient she can be.   Additional Resources:   Tessa on Instagram: @seeing_life_clearly   Tessa's website: https://www.tessa.parry-wingfield.com  

Join Dr. Martin in today's episode of The Doctor Is In Podcast.  

When it comes to your pet's health, there is no word more terrifying than "cancer." The immediate reaction is often fear, followed by a difficult question: "I wouldn't put myself through chemo, so why would I put my dog through it?"In this episode, we sit down with Dr. Rance Gamblin, a veterinary oncologist formerly at Metropolitan Veterinary Hospital and now professor at Mississippi State College of Veterinary Medicine with 24+ years of experience and a calming presence that could soothe even the most "OCD" pet parent (just ask Alice!). Dr. Gamblin helps us navigate the emotional and medical complexities of a cancer diagnosis, explaining why veterinary oncology is often far more compassionate and focused on quality of life than human medicine.In this episode, we discuss:- The "Quality of Life" Philosophy: Why the goals of pet oncology differ from human oncology—focusing on making pets feel better for longer, rather than "curing at any cost."- Common Culprits: A look at the most frequent cancers Dr. Gamblin treats, including Lymphoma, Mast Cell Tumors, and Osteosarcoma.- The Truth About Side Effects: Do dogs lose their hair? Dr. Gamblin shares the reality of how pets handle chemotherapy (hint: there's a lot more tail-wagging involved than you'd think).- Treatment Innovations: Insights into the Yale vaccine study and the fascinating science behind the Melanoma vaccine. -Proactive Pet Parenting: Why Dr. Gamblin's biggest pet peeve is the "let's just watch it" approach, and why your pet's breath or a quick rectal exam could be a lifesaver.- Knowing When It's Time: A heart-to-heart on the "Big Four" indicators of quality of life and how to navigate the toughest decision a pet owner can make.Dr. Rance Gamblin earned his BS in Biology from Mississippi State and completed his residency in Oncology and Hematology at The Ohio State University. For over two decades, he has been a pillar of the veterinary community at Metropolitan Veterinary Hospital, known for his expertise, his steady hand, and an accent you'll just have to hear for yourself to guess where he's from! He is currently a professor at Mississippi State College of Veterinary Medicine.--What started during the COVID-19 lockdown with one baby gorilla at the Cleveland Zoo has grown into a channel loved by animal fans around the world. I'm a one-person operation—filming, editing, narrating, and sharing the most heartfelt moments of baby gorillas, orangutans, elephants, and other zoo animals. Whether it's Jameela's emotional journey or Clementine's first steps, each video brings you closer to the animals and their stories. If you love watching real animal behavior, learning fun facts, and supporting conservation through storytelling—this is your place! Subscribe to Larry's Animal Safari on YouTube @larrysanimalsafari ---Support our sponsor for this episode Blue Buffalo by visiting bluebuffalo.com. BLUE Natural Veterinary Diet formulas offer the natural alternative in nutritional therapy. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents.---All footage is owned by SLA Video Productions.

When it comes to your pet's health, there is no word more terrifying than "cancer." The immediate reaction is often fear, followed by a difficult question: "I wouldn't put myself through chemo, so why would I put my dog through it?"In this episode, we sit down with Dr. Rance Gamblin, a veterinary oncologist formerly at Metropolitan Veterinary Hospital and now professor at Mississippi State College of Veterinary Medicine with 24+ years of experience and a calming presence that could soothe even the most "OCD" pet parent (just ask Alice!). Dr. Gamblin helps us navigate the emotional and medical complexities of a cancer diagnosis, explaining why veterinary oncology is often far more compassionate and focused on quality of life than human medicine.In this episode, we discuss:- The "Quality of Life" Philosophy: Why the goals of pet oncology differ from human oncology—focusing on making pets feel better for longer, rather than "curing at any cost."- Common Culprits: A look at the most frequent cancers Dr. Gamblin treats, including Lymphoma, Mast Cell Tumors, and Osteosarcoma.- The Truth About Side Effects: Do dogs lose their hair? Dr. Gamblin shares the reality of how pets handle chemotherapy (hint: there's a lot more tail-wagging involved than you'd think).- Treatment Innovations: Insights into the Yale vaccine study and the fascinating science behind the Melanoma vaccine. -Proactive Pet Parenting: Why Dr. Gamblin's biggest pet peeve is the "let's just watch it" approach, and why your pet's breath or a quick rectal exam could be a lifesaver.- Knowing When It's Time: A heart-to-heart on the "Big Four" indicators of quality of life and how to navigate the toughest decision a pet owner can make.Dr. Rance Gamblin earned his BS in Biology from Mississippi State and completed his residency in Oncology and Hematology at The Ohio State University. For over two decades, he has been a pillar of the veterinary community at Metropolitan Veterinary Hospital, known for his expertise, his steady hand, and an accent you'll just have to hear for yourself to guess where he's from! He is currently a professor at Mississippi State College of Veterinary Medicine.--What started during the COVID-19 lockdown with one baby gorilla at the Cleveland Zoo has grown into a channel loved by animal fans around the world. I'm a one-person operation—filming, editing, narrating, and sharing the most heartfelt moments of baby gorillas, orangutans, elephants, and other zoo animals. Whether it's Jameela's emotional journey or Clementine's first steps, each video brings you closer to the animals and their stories. If you love watching real animal behavior, learning fun facts, and supporting conservation through storytelling—this is your place! Subscribe to Larry's Animal Safari on YouTube @larrysanimalsafari ---Support our sponsor for this episode Blue Buffalo by visiting bluebuffalo.com. BLUE Natural Veterinary Diet formulas offer the natural alternative in nutritional therapy. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents. At Blue Buffalo, we have an in-house Research & Development (R&D) team with over 300 years' experience in well-pet and veterinary therapeutic diets, over 600 scientific publications, and over 50 U.S. patents.---All footage is owned by SLA Video Productions.

Researchers evaluated the efficacy and outcomes of complete surgical excision of perianal melanomas from 59 horses. Read the full article here: https://equimanagement.com/research-medical/research/treatment-outcomes-for-perianal-melanoma-removal-in-horses/Mentioned in this episode:EquiManagement on Audio All the articles you have come to love in EquiManagement Magazine are now available in this podcast for free. Each article is released as its own separate episode to make them quick and easy to listen to. EquiManagement always has the latest insights on equine health, veterinary practice management, and veterinarian wellness.

Dr. Lisa Duhaime is a board-certified medical oncologist at Peeples Cancer Institute at Hamilton Medical Center in Dalton, Georgia.For more information about Peeples Cancer Institute, call 844-PCI-HOPE or visit VitruvianHealth.com/cancer.This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem.

Australia has the highest melanoma rates in the world, and with around seventy per cent of melanomas appearing on highly visible areas like the face, head and neck, many patients' needing life-saving cancer surgery, are left with initial disfigurement as well as impaired vision, breathing, speech or facial movement after. Reconstructive procedures are critical to restoring these essential functions, from blinking to protect the eye, to nasal airflow for breathing, and facial movement for speech and expression.

La Dra. Lisa Duhaime es oncóloga médica certificada por la junta del Peeples Cancer Institute en Dalton, Georgia.Para obtener más información sobre Peeples Cancer Institute, llame al 844-PCI-HOPE o visite VitruvianHealth.com/cancer.Este podcast de ninguna manera busca diagnosticar o tratar enfermedades o reemplazar la atención médica profesional. Consulte a su proveedor de atención médica si tiene un problema de salud. La versión en español es una traducción del original en inglés. En caso de discrepancia, prevalecerá el original en inglés (Health for Life: https://health-for-life.captivate.fm/listen).This program in no way seeks to diagnose or treat illness or to replace professional medical care. Please see your healthcare provider if you have a health problem. The Spanish version is a translation of the original in English. In case of a discrepancy, the English original (Health for Life: https://health-for-life.captivate.fm/listen) will prevail.

A stage-IV metastatic melanoma diagnosis is often delivered with words like incurable and life-limiting. In this deeply moving episode, Dr. Michael Karlfeldt sits down with Kevin Donaghy, an IT consultant from Melrose, Scotland, who has lived more than six years beyond his diagnosis—and transformed his personal cancer journey into a global mission of hope. Through his lived experience and the revolutionary impact of immunotherapy, Kevin offers rare insight into what it truly means to navigate advanced cancer with courage, honesty, and humanity.Kevin shares the emotional realities of being told his cancer was medically incurable, the isolation and fear that followed, and how finding community during COVID lockdowns became a turning point for his mental health. Out of that connection grew Stories of Cancer and Hope, an anthology of 39 real-life cancer stories—some triumphant, some heartbreaking—all designed to offer solidarity to those who feel alone. Listeners will hear powerful reflections on cancer ghosting, mental health struggles, redefining hope, and why shared stories can be as life-saving as treatment itself.This episode is essential listening for cancer patients, survivors, caregivers, and healthcare professionals alike. Whether you are newly diagnosed, supporting a loved one, or seeking deeper understanding of the emotional side of cancer, Kevin's story reminds us that hope is not a single outcome—it is something that evolves, connects, and endures.Key Topics CoveredLiving beyond a stage-IV metastatic melanoma diagnosisThe emotional shock of being told cancer is “incurable”Immunotherapy for melanoma: promise, risks, and realitiesCancer isolation, loneliness, and “cancer ghosting”Mental health challenges and suicidal ideation in cancer patientsThe healing power of community and shared lived experienceCreating Stories of Cancer and Hope and distributing thousands of free booksHow hope changes throughout the cancer journeySupporting families and caregivers through understanding and empathyConnect with Kevin Donaghy & Stories of Cancer and HopeWebsite: https://www.storiesofcancerandhope.co.uk/Social Media:LinkedIn: Kevin DonaghyInstagram: Kevin A Donaghy, Stories of Cancer and HopeBluesky: storiescancerhope.bsky.socialAmazon Author Page: https://www.amazon.com/stores/Kevin-Donaghy/author/B0D7S7LRMJ?ref=ap_rdr&shoppingPortalEnabled=true&ccs_id=d17d4d5b-3bb2-4adf-87a3-b274a0211630 -----------------------------------------------A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health ThreatGrab my book here: https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 Unleashing 10X Power: A Revolutionary Approach to Conquering CancerGet it here: https://store.thekarlfeldtcenter.com/products/unleashing-10x-powerPrice: $24.99100% Off Discount Code: CANCERPODCAST1 Healing Within: Unraveling the Emotional Roots of CancerGet it here: https://store.thekarlfeldtcenter.com/products/healing-withinPrice: $24.99100% Off Discount Code: CANCERPODCAST2-----------------------------------------------Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

Popular media leverage weak study to criticize RFK Jr.'s rethink of standard recommendations for saturated fat avoidance; Poor quality plant-based diets hike cardio risk; A listener complains his lp(a) is going up with age despite his healthy diet, lifestyle; Scientists pinpoint cocoa ingredient that slows aging; Berry proanthocyanidins preserve brain power; Tattooing may promote inflammation, undermine immunity.

Q-BANK: https://patreon.com/highyieldfamilymedicineIntro (0:35),Venous leg ulcers (1:45),Arterial (ischemic) ulcers (2:58),Diabetic foot ulcers (4:42),Pressure injuries (6:10),Pyoderma gangrenosum (8:24),Burns (9:36),Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis (13:12),Warfarin necrosis (14:33),Necrotizing fasciitis (15:21),Rocky Mountain Spotted Fever (16:22),Erythema nodosum (17:35),Lipoma (19:08),Epidermal inclusion cyst (20:00),Dermatofibroma (20:51),Cherry hemangiomas (21:52),Seborrheic ketatosis (22:37),Actinic keratosis (23:41),Basal cell carcinoma (24:47),Squamous cell carcinoma (26:24),Melanoma (28:05),Kaposi sarcoma (30:29),Mycosis fungoides (31:26),Practice questions (32:50)

Today's guest is Tessa Parry-Wingfield, global communications consultant, public speaker, and survivor of ocular melanoma, a very rare form of eye cancer that affects about 6 people per million annually. She has found purpose in her adversity and ironically "sees life clearly" despite her vision issues.We talk about learning to live with a prosthetic eye and monocular vision, the challenges of rare cancers, eye and vision health (see your eye doctor regularly), finding purpose and clarity post diagnosis, and so much more!Resources:Tessa's Website: Tessa Parry-Wingfield | Speaker + Storyteller | Seeing life clearly |Tessa's Instagram: https://www.instagram.com/seeing_life_clearly/Tessa's LinkedIn: Tessa Parry-Wingfield | LinkedInFollow:Follow me: https://www.instagram.com/melissagrosboll/My website: https://melissagrosboll.comEmail me: drmelissagrosboll@gmail.com

Veterinarian David Levine is a boarded surgeon who frequently deals with equine skin issues such as melanoma. Learn what melanomas are, how to recognize them, and what can be done to treat them.My Senior Horse - Episode 35 Guests and Links:Guest: Dr. David Levine, DVMConnect with Host: Kimberly S. Brown of Editorial Director of My Senior Horse | Email Kim (kbrown@equinenetwork.com) | Follow Kim on LinkedIn (@kimberlylsbrown)

Did Cankles Caligula forget he has a son with Melanoma or is "her son" just not his? MAGAT House introduces silly excuse for a healthcare bill. More photos from the Epstein Estate and the ones yet to come are described as deeply disturbing. ICE goon gets taken to police station after attempting to kidnap immigrants. Maryland court allows sexual abuse lawsuit against Linda McMahon go forward. 

Melanoma used to have almost no effective treatment options. Now? Immunotherapy is changing lives — and Oxford's Dr. Mark Middleton joins us to unpack the science, the turning points, and the innovations reshaping melanoma care.In this episode, he reflects on decades of research — from the early trials that taught researchers what not to do, to the breakthroughs in checkpoint inhibition and precision approaches that dramatically improved outcomes. We also dive into MyMelanoma, a nationwide effort gathering real-world patient data to answer questions traditional trials often leave behind.Takeaways:What researchers learned from early immunotherapy trial failures — and how those lessons shaped today's strategies The evolving science behind checkpoint inhibitors and why certain patients respond more durably than othersHow MyMelanoma is uncovering insights on risk, survivorship, lifestyle factors, and real-world outcomes at scale The future of melanoma treatment, including biomarkers, combinatorial approaches, and better trial designs

Welcome to Session 1 of the Eye Believe Survivorship Seminar 2025! This 8:00 AM session features renowned ocular oncologist Dr. MATERIN (Duke Health) as he presents “Yesterday, Today & Tomorrow in Ocular Melanoma.” In this powerful opening session, Dr. Materin walks attendees through:

In this episode, we interview Danny Powell, an ocular melanoma (OM) patient whose tumor was identified early thanks to his eye doctor noticing a change and acting quickly. Danny explains his diagnosis, his treatment with brachytherapy, and how he later discovered that his grandmother also had OM—an extremely rare family connection. This prompted genetic testing, which revealed that Danny carries a BAP1 gene mutation. He discusses what that means for his ongoing care, his decision to join a clinical study, and the importance of regular surveillance scans. Whether you're an OM patient, caregiver, or medical professional, this episode provides practical insight into early detection, genetic risk factors, and patient involvement in research.

TJ Sharpe is a stage four melanoma survivor, nationally known patient advocate, keynote speaker, digital health technologist, and consultant to the life sciences industry. Drawing from personal experience and his work in clinical research, TJ empowers healthcare and pharma organizations to prioritize patient-centric approaches to trials, communication, and support. He shares his story to inspire others facing adversity and to promote transformative improvements in healthcare. In this episode of Marketer of the Day, TJ Sharpe joins Robert Plank to recount his journey from being diagnosed with melanoma in his twenties, through a life-threatening recurrence that led him to cutting-edge clinical trials, to his eventual recovery and the launch of his advocacy career. TJ details his navigation of the medical system, the emotional and logistical challenges faced by patients, and how gratitude and support systems are as important as medical interventions. The discussion spotlights the importance of accessible, transparent information, and patient empowerment within clinical research. TJ also describes his consulting work to help organizations incorporate patient voices and streamline drug development for the benefit of all. Quotes: “If you don't know all your options, you're not making the most informed choice for you.” “Finding your ‘ninja'—that support person—makes all the difference in getting through a cancer journey.” “It's not just about surviving cancer, it's about making a difference for millions more who will walk this path.” Resources: Visit TJ Sharpe's Website Connect with TJ Sharpe on LinkedIn

The Naked Scientists welcome the return of a new series of Titans of Science, where the world's scientific, medical, and technological pioneers tell us about the significance of their work. Today's episode features Georgina Long, the director of the Melanoma Institute Australia, who has used groundbreaking techniques to overcome the disease. Melanoma is a type of cancer that is particularly common in Georgina's homeland, and she has been telling Chris Smith how her work has made her one of Australia's most recognisable scientists... Like this podcast? Please help us by supporting the Naked Scientists

Can natural herbs aid recovery from anorexia? What an analysis of Hitler's DNA tells us about how genes shaped his personality; Can surgical anesthesia accelerate memory loss?  Bananas could be interfering with your smoothie's health benefits; Not just sun, but pesticides and herbicides increase risk for melanoma; Chemical residues on produce impair male fertility; Proliferation of fast-paced social media videos are dumbing us down; Doctors aren't less resilient, the demands of medicine are just fostering unprecedented levels of physician burnout.

Redheads are bullied, fetishized, and medically misunderstood. Jessica Wynn is here to color in the facts about being a ginger on this Skeptical Sunday!Welcome to Skeptical Sunday, a special edition of The Jordan Harbinger Show where Jordan and a guest break down a topic that you may have never thought about, open things up, and debunk common misconceptions. This time around, we're joined by writer and researcher Jessica Wynn!Full show notes and resources can be found here: jordanharbinger.com/1219On This Week's Skeptical Sunday:The MC1R gene mutation causes red hair, pale skin, and freckles, but also influences pain processing, drug metabolism, and other biological functions throughout the body.Redheads experience pain differently — they tolerate electric shocks better but are more sensitive to heat and cold, requiring adjusted medical treatment approaches.Redheads have significantly higher melanoma risk because they produce less protective melanin, making sunscreen essential and frequent sun exposure dangerous.Redheads face ongoing discrimination and fetishization — from childhood bullying to adult harassment — despite red hair being a normal genetic variation affecting one to two percent of the population.Research on redheads' unique genetics is advancing pain treatment for everyone. Understanding genetic diversity helps medicine better serve all patients, not just those with red hair.Connect with Jordan on Twitter, Instagram, and YouTube. If you have something you'd like us to tackle here on Skeptical Sunday, drop Jordan a line at jordan@jordanharbinger.com and let him know!Connect with Jessica Wynn at Instagram and Threads, and subscribe to her newsletters: Between the Lines and Where the Shadows Linger!And if you're still game to support us, please leave a review here — even one sentence helps! Sign up for Six-Minute Networking — our free networking and relationship development mini course — at jordanharbinger.com/course!Subscribe to our once-a-week Wee Bit Wiser newsletter today and start filling your Wednesdays with wisdom!Do you even Reddit, bro? Join us at r/JordanHarbinger!This Episode Is Brought To You By Our Fine Sponsors:SimpliSafe: 50% off + 1st month free: simplisafe.com/jordanAirbnb: airbnb.com/hostApretude: Apretude.com or call 1-888-240-034Quiltmind: Email jordanaudience@quiltmind.com to get started or visit quiltmind.com for more infoWhat Was That Like: Listen here or wherever you find fine podcasts!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.